SARS-CoV-2 Infection Dysregulates the Metabolomic and Lipidomic Profiles of Serum
Creators
- 1. CIC bioGUNE
- 2. BIOCRUCES
- 3. OSARTEN
- 4. ATLAS MOLECULAR PHARMA
- 5. CIC bioGUNE/CIBERehd
- 6. Cedars Sinai
Description
COVID-19 is a systemic infection that exerts significant impact on the metabolism. Yet, there is little information on how SARS-CoV-2 affects metabolism. Using NMR spectroscopy, we measured the metabolomic and lipidomic serum profile from 263 (training cohort) + 135 (validation cohort) symptomatic patients hospitalized after positive PCR testing for SARS-CoV-2 infection. We also established the profiles of 280 persons collected before the coronavirus pandemic started. Principal-component analysis discriminated both cohorts, highlighting the impact that the infection has on overallmetabolism. The lipidomic analysis unraveled a pathogenic redistribution of the lipoprotein particle size and composition to increase the atherosclerotic risk. In turn, metabolomic analysis reveals abnormally high levels of ketone bodies (acetoacetic acid, 3-hydroxybutyric acid, and acetone) and 2- hydroxybutyric acid, a readout of hepatic glutathione synthesis and marker of oxidative stress. Our results are consistent with a model in which SARS-CoV-2 infection induces liver damage associated with dyslipidemia and oxidative stress.
Files
PIIS2589004220308373.pdf
Files
(3.7 MB)
Name | Size | Download all |
---|---|---|
md5:8ab5ecf36074242d1be4abb642cdfb6b
|
3.7 MB | Preview Download |